Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 May 2011

Brevet Marie, Shimizu Shigeki, Bott Matthew J, Shukla Neerav, Zhou Qin, Olshen Adam B, Rusch Valerie, Ladanyi Marc

Abstract excerpt

INTRODUCTION: To identify new therapeutic approaches in malignant mesothelioma (MM), we examined the expression and activation of receptor tyrosine kinases (RTKs) and the effects of specific RTK inhibitors and the mammalian target of rapamycin (mTOR) inhibitor rapamycin; the latter being of special interest in MM given the recent linkage between NF2 loss and mTOR activation. METHODS: We performed a screen for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mesothelioma
Share to Pleural Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-met

Share to Receptor, IGF Type 1

Share to Receptors, Growth Factor

Share to Sirolimus

Share to Sulfones

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 21774103
DOI: 10.1097/jto.0b013e318215a07d

Genes

EGFR
MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.PMID 21774103Read ↗

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplificationSemantic proximity Read ↗

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.Semantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

The role of the HGF/Met axis in mesothelioma.Semantic proximity Read ↗

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivationSemantic proximity Read ↗

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Semantic proximity Read ↗

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Semantic proximity Read ↗

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.Semantic proximity Read ↗

Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.Semantic proximity Read ↗

Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.Semantic proximity Read ↗

Combination MEK and mTOR inhibitor therapy is active in models of glioblastomaSemantic proximity Read ↗

Ror1 Is a Pseudokinase That Is Crucial for Met-Driven TumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.